info@seagull-health.com
SeagullHealth
语言:
search
new
Elglustat detailed instructions, medical insurance, price, efficacy, side effects
500
Article source: Seagull Pharmacy
Jul 04, 2025

Elglustat is a new oral drug used to treat type 1 Gaucher disease in adults. This drug works by reducing the synthesis of glucocerebroglycan, and has proven efficacy in patients who have or have not received enzyme replacement therapy, making it a competitive new option. This article will provide a detailed introduction to the medical insurance coverage, price information, efficacy, and possible side effects of Elglustat.

Elglustat detailed instructions, medical insurance, price, efficacy, side effects

In some countries, Elglustat may be partially covered by the medical insurance system or private insurance.

Medical insurance and price

Patients should consult their insurance company before purchasing to understand the specific reimbursement policy and required medical certificates. The price of the drug varies from region to region.

Medical insurance coverage

Elglustat is not yet available in China and has not entered the Chinese medical insurance system. Therefore, for the Chinese market, there is no medical insurance reimbursement for the time being. The medical insurance policies of other countries need to be determined according to local specific regulations.

Price factors

Due to the high R&D cost of Elglustat, the market price is usually more expensive. When choosing this drug, patients need to consider not only the efficacy, but also their own economic situation and insurance coverage.

Efficacy and indications

Elglustat is mainly used to treat mild and moderate Gaucher disease in adult patients, the cause of which is related to β-glucosidase deficiency. It is suitable for long-term treatment of adult patients with type 1 Gaucher disease who are detected as CYP2D6 extensive metabolites (EMs), intermediate metabolites (IMs) or poor metabolizers (PMs) by FDA-approved tests.

Principle of action

Elglustat improves the symptoms of Gaucher disease patients by inhibiting the action of specific enzymes and reducing the synthesis of glucocerebroglycan in the body. This is an important treatment option for patients with a suitable genetic background.

Clinical effect

Multiple clinical trials have shown that significant clinical improvements can be observed after using Elglustat, including normalization of blood indicators and improved quality of life, whether in newly diagnosed patients or those who have received other treatments.

Precautions for use

In order to achieve the best treatment effect and avoid unnecessary risks, patients need to pay attention to some matters during the use of Elglustat. These include regular checkups, interactions with other drugs, and lifestyle adjustments.

Regular monitoring

During the use of Elglustat, your doctor may recommend regular blood tests, bone density tests, and liver function tests to evaluate the treatment effect and safety.

Drug interactions

Strong CYP3A inducers can reduce the concentration of Elglustat and may affect the efficacy; at the same time, Elglustat may also change the metabolic process of other drugs (such as P-gp substrates or CYP2D6 substrates), so caution should be exercised when taking drugs in combination.

Daily life recommendations

Patients should maintain a healthy lifestyle in their daily lives, eat a reasonable diet, exercise moderately, follow the doctor's instructions, and take medications on time. If you have any discomfort or questions, you should communicate with medical professionals in a timely manner.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Elglustat(Cerdelga)
Elglustat(Cerdelga)
Long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are...
WeChat Scan
Free Inquiry
Recommended Articles
Side effects of Pirtobrutinib
Pirtobrutinib is a kinase inhibitor. Like most powerful drugs, the use of Pirtobrutinib is accompanied by a series of potential side effects. This article will explore the side effects, miti...
Precautions for Pirtobrutinib
As an oral targeted drug, the standard dose of Pirtobrutinib is 200mg once daily, but special attention should be paid to its safety issues such as liver toxicity and infection risk. Patients sho...
How effective is the targeted drug Pirtobrutinib
Pirtobrutinib(Jaypirca) is a new type of targeted therapy drug, mainly used to treat relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma ...
How to use Pirtobrutinib
Pirtobrutinib is mainly used to treat relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients need to strictly follow the...
Indications of Elglustat
Elglustat is a drug used to treat Gaucher disease type 1 (GD1), and its indication is mainly for adult patients confirmed by specific metabolic enzyme tests. The drug works by regulating metaboli...
How much does Elglustat cost per box?
Elglustat is an oral targeted drug for the treatment of type 1 Gaucher disease, produced by Sanofi in France. The drug has not yet been launched in China, nor has it been included in the medical ...
How to buy Elglustat(Cerdelga)?
Elglustat(Cerdelga) is a drug used to treat Gaucher disease type 1.The drug is mainly purchased through overseas channels, such as the original drug from Sanofi in France, and the price is relati...
Dosage of Elglustat
Elglustat is a drug used to treat Gaucher disease type 1. Its dosage needs to be adjusted according to the patient's CYP2D6 metabolic status. This article will focus on the dosage, purchase c...
Related Articles
What Are the Side Effects of Eliglustat (Cerdelga)?
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor. It has been approved by the U.S. FDA for the treatment of adult patients with Type 1 Gaucher disease. Its eligible recipients must be CY...
Precautions for Eliglustat (Cerdelga) Administration
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor. It is approved for the long-term treatment of adult patients with Type 1 Gaucher disease (GD1) who have been identified as CYP2D6 extens...
How to Use Eliglustat (Cerdelga)
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor that received its first approval in the United States in 2014. As a long-acting therapeutic agent for Type 1 Gaucher disease, it provides...
What Kind of Drug Is Eliglustat (Cerdelga)?
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor that received its first approval in the United States in 2014. As a targeted therapy for Type 1 Gaucher disease, it acts as a substrate r...
How to Purchase Eliglustat (Cerdelga)
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor. It is specifically indicated for the long-term treatment of adult patients with Type 1 Gaucher disease who have been confirmed as CYP2D6...
How to Use Eliglustat (Cerdelga)
Eliglustat (Cerdelga) is a selective glucosylceramide synthase inhibitor indicated for the long-term treatment of Type 1 Gaucher disease (GD1) in adults. Its efficacy and effectiveness are highly depe...
What Are the Side Effects of Eliglustat (Cerdelga)?
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor used for the long-term treatment of Type 1 Gaucher Disease in adults, with eliglustat as its active ingredient.What Are the Side Effects ...
Precautions for Eliglustat (Cerdelga) Administration
Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor indicated for the long-term treatment of Type 1 Gaucher Disease (GD1) in adults. Its efficacy and safety are highly dependent on individu...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved